Manuel Hidalgo Medina has served as a member of Guardant Health's Board since July 2024 and serves on the Nominating and Corporate Governance Committee. He has more than 20 years of experience in translational and clinical research in anticancer drug development with a particular emphasis on gastrointestinal cancers.
Dr. Hidalgo has served as Director of the GI Cancer Center at New York University (NYU) since 2025, where he oversees clinical and translational research in GI medical oncology, and as a Professor of Medicine at NYU since 2025. Prior to his current position, he served as chief of the division of hematology and medical oncology at Weill Cornell Medicine from 2019 to 2025, and as chief of hematology and medical oncology at Beth Israel Deaconess Medical Center in Boston and clinical director of the Rosenberg Clinical Cancer Center from 2015 to 2019, during which time he was the Theodore W. and Evelyn G. Berenson professor of medicine at Harvard Medical School. He also held leadership positions at the Spanish National Cancer Research Centre (CNIO) in Madrid and at the Kimmel Comprehensive Cancer Center, where he was director of the gastrointestinal oncology program.
Dr. Hidalgo currently serves as a member of the Board of Directors of Bristol-Myers Squibb Company. He received his Medical Degree from the University of Navarra in Pamplona, Spain, and a Doctorate in infectious diseases and cancer from the University Autonoma of Madrid, Spain. He completed his Residency training in Medical Oncology at the Hospital 12 de Octubre in Madrid and his Fellowship in Medical Oncology at the University of Texas Health Science Center in San Antonio, Texas, where he also served as an Assistant Professor of Medicine.